Daunorubicin/cytarabine
Liposomal daunorubicin/cytarabine is a fixed-dose combination of liposomal bound cytarabine and daunorubicin that delivers the two medications in a 5:1 molar ratio.
![]() Cytarabine | |
![]() daunorubicin | |
Combination of | |
---|---|
Cytarabine | Antimetabolite |
daunorubicin | Anthracycline |
Clinical data | |
Trade names | Vyxeos |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
KEGG |
It is used in the treatment of therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).[1][2][3][4]
References
- "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2019-03-19.
- "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.
- Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML". OncoTargets and Therapy. 11: 3425–3434. doi:10.2147/OTT.S141212. PMC 6003284. PMID 29928134.
- Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica. 111 (5): 455–466. doi:10.23736/S0026-4806.20.07017-2. PMID 32955826. S2CID 221842680.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.